Angiogenic gene therapy in patients with nonrevascularizable ischemic heart disease : a phase 2 randomized, controlled trial of AdVEGF121 (AdVEGF121) versus maximum medical treatment

Journal article

Peer reviewed

D. J Stewart, J. D Hilton, F. O Mendelsohn, N Dib, P Page, J Ducas, S Plante, J Sullivan, J Macko, C Rasmussen, …

Gene therapy, Vol.13(21), pp.1503-1511

11/01/2006

Abstract

Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy

Applied cell therapy and gene therapy

Biological and medical sciences

Biotechnology

Cell differentiation, maturation, development, hematopoiesis

Cell physiology

Fundamental and applied biological sciences. Psychology

Gene therapy

Health. Pharmaceutical industry

Industrial applications and implications. Economical aspects

Medical sciences

Molecular and cellular biology

Transfusions. Complications. Transfusion reactions. Cell and gene therapy

1 Record Views

Title: Angiogenic gene therapy in patients with nonrevascularizable ischemic heart disease : a phase 2 randomized, controlled trial of AdVEGF121 (AdVEGF121) versus maximum medical treatment
Creators: D. J Stewart - St. Michael's Hospital
J. D Hilton - Victoria Heart Institute Foundation
F. O Mendelsohn - St. Vincent's Birmingham
N Dib - Arizona Heart Institute
P Page - Hôpital du Sacré-Cœur de Montréal
J Ducas - Manitoba Health
S Plante - Montreal Heart Institute
J Sullivan - Queen Elizabeth II Health Sciences Centre
J Macko - GenVec
C Rasmussen - GenVec
et al.
Publication Details: Gene therapy, Vol.13(21), pp.1503-1511
Publisher: Nature Publishing Group
Number of pages: 9
Identifiers: 991006261451602656
Academic Unit: Cardiology
Language: English
Resource Type: Journal article